TW9
TW9 is a potent dual inhibitor simultaneously targeting BET and HDAC proteins with KDs of 0.069 μM, 0.231 μM for BRD4 (1), BRD4 (2), and an IC50 of 0.29 μM for HDAC1, respectively. TW9 is a newly generated adduct of the BET inhibitor (+) -JQ1 and class I HDAC inhibitor CI994 (HY-50934). TW9 shows high potency in suppressing tumor growth in pancreatic ductal adenocarcinoma (PDAC). TW9 improves the efficacy of the chemotherapeutic agent Gemcitabine (HY-17026).
Product Specifications
CAS Number
2614417-90-0
UNSPSC
12352005
Target
Epigenetic Reader Domain; HDAC
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Field of Research
Cancer
Smiles
CC1=C(C)SC2=C1C(C3=CC=C(C=C3)Cl)=N[C@@H](CC(NC4=CC=C(C=C4)C(NC5=C(C=CC=C5)N)=O)=O)C6=NN=C(C)N26
Molecular Formula
C32H28ClN7O2S
Molecular Weight
610.13
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD4; HDAC1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
IL9R (Interleukin-9 Receptor, IL-9 Receptor, IL-9R, CD129)
IL9R (Interleukin-9 Receptor, IL-9 Receptor, IL-9R, CD129)
MOB1A (Mps One Binder Kinase Activator-like 1A, MOB1, MATS1, Mob4B, C2orf6, MOBK1B, MOBKL1B)